Immunity
for Humanity

A new era for combatting infectious diseases.

We are an independent laboratory developing monoclonal antibodies to revolutionize the treatment of infectious diseases including yellow fever, dengue, Zika, Covid-19, and viruses from the betacoronavirus family.

Mabloc imagem

OUR GOAL IS TO AMELIORATE SUFFERING FROM INFECTIOUS DISEASES.

Monoclonal antibodies (mAbs) developed in our laboratory can be used for the treatment and prevention of infectious diseases and represent a powerful strategy for combating global and local epidemics.

MABLOC has already developed several mAbs (with its partners) that can be used for the treatment and prevention of infectious diseases including yellow fever, dengue, Zika, and Covid-19.

FIRST CLASS TEAM

Esper Kallás

MD, PhD

An expert in infectious diseases, Esper Kallás is a physician scientist and Professor at the USP Medical School and led the fight against the Brazilian Coronavirus pandemic at the Hospital das Clínicas de São Paulo. He also headed the clinical trial of the Brazilian Coronavac vaccine.

David Watkins

PhD

David Watkins is a Professor of pathology at the George Washington University Medical School. He is a basic scientist with experience in the development of prophylactic and treatment approaches to infectious diseases.

Dennis Burton

PhD

Dennis is one of the world's foremost monoclonal antibody experts, chairman of Immunology and Microbiological Science at the Scripps Research Institute, California. He is also a member of the Steering Committee of Harvard and MIT’s Ragon Institute.

Michael Wyand

PhD

Michael Wyand is an experienced Pharmaceutical Executive who has founded and traded several pharmaceutical companies including companies that produce mAbs. He is a senior professional with executive management experience in both private and public companies.

Mabloc’s Dream Team

Pipeline